PCRX - Pacira BioSciences, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Parsippany,
United States
Type: Equity
PCRX price evolution
PCRX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $247.05 | $184.05 | $153.3 | |
| Short term investments | $157.17 | $141.84 | $125.28 | |
| Net receivables | $100.65 | $104.78 | $101.64 | $105.56 |
| Inventory | $111.86 | $103.44 | $96.78 | $104.35 |
| Total current assets | $689.97 | $632.21 | $543.11 | $509.99 |
| Long term investments | $36.5 | $36.54 | $38.46 | |
| Property, plant & equipment | $220.68 | $225.11 | $230.43 | $234.95 |
| Goodwill & intangible assets | $617.86 | $632.18 | $646.5 | |
| Total noncurrent assets | $1014.61 | $1040.21 | $1064.39 | |
| Total investments | $193.67 | $178.38 | $163.74 | |
| Total assets | $1521.69 | $1646.82 | $1583.32 | $1574.39 |
| Current liabilities | ||||
| Accounts payable | $19.37 | $18.73 | $8.98 | $15.7 |
| Deferred revenue | ||||
| Short long term debt | $9.15 | $17.64 | $17.44 | |
| Total current liabilities | $306.4 | $92.69 | $93.44 | $97.38 |
| Long term debt | $385.89 | $639.45 | $564.13 | $568.6 |
| Total noncurrent liabilities | $674.85 | $597.72 | $606.87 | |
| Total debt | $648.6 | $581.78 | $586.04 | |
| Total liabilities | $772.11 | $767.54 | $691.16 | $704.26 |
| Shareholders' equity | ||||
| Retained earnings | -$222.4 | -$78.93 | -$97.82 | -$106.8 |
| Other shareholder equity | $0.12 | $0.1 | $0.15 | $0.25 |
| Total shareholder equity | $879.28 | $892.16 | $870.13 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $153.3 | $104.14 | $585.58 | $99.96 |
| Short term investments | $125.28 | $184.51 | $70.83 | $421.7 |
| Net receivables | $105.56 | $98.4 | $96.32 | $53.05 |
| Inventory | $104.35 | $96.06 | $98.55 | $64.65 |
| Total current assets | $509.99 | $498.33 | $866.05 | $651.62 |
| Long term investments | $38.46 | $64.38 | $21.99 | $109.48 |
| Property, plant & equipment | $234.95 | $254.39 | $264.81 | $211.18 |
| Goodwill & intangible assets | $646.5 | $703.79 | $769.14 | $196.07 |
| Total noncurrent assets | $1064.39 | $1182.87 | $1209.31 | $622.89 |
| Total investments | $163.74 | $248.89 | $92.82 | $531.18 |
| Total assets | $1574.39 | $1681.2 | $2075.35 | $1274.51 |
| Current liabilities | ||||
| Accounts payable | $15.7 | $15.22 | $10.54 | $10.43 |
| Deferred revenue | $10.13 | |||
| Short long term debt | $17.44 | $42.77 | $382.59 | $157.07 |
| Total current liabilities | $97.38 | $147.77 | $521.12 | $253.33 |
| Long term debt | $568.6 | $655.82 | $746.26 | $384.06 |
| Total noncurrent liabilities | $606.87 | $758.42 | $823.83 | $401.5 |
| Total debt | $586.04 | $763.39 | $1128.85 | $541.13 |
| Total liabilities | $704.26 | $906.19 | $1344.94 | $654.83 |
| Shareholders' equity | ||||
| Retained earnings | -$106.8 | -$148.75 | -$211.9 | -$253.88 |
| Other shareholder equity | $0.25 | $0.14 | $0.17 | $0.32 |
| Total shareholder equity | $870.13 | $775.01 | $730.41 | $619.69 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $168.57 | $178.02 | $167.12 | $181.24 |
| Cost of revenue | $44.26 | $47.42 | $47.69 | |
| Gross Profit | $129.71 | $133.76 | $119.7 | $133.55 |
| Operating activities | ||||
| Research & development | $20.34 | $18.24 | $19.46 | |
| Selling, general & administrative | $68.13 | $72.03 | $65.8 | |
| Total operating expenses | $107.76 | $105.52 | $106.49 | $100.38 |
| Operating income | $28.24 | $13.21 | $33.17 | |
| Income from continuing operations | ||||
| EBIT | $40.47 | $16.96 | $37.11 | |
| Income tax expense | $4.61 | $17.7 | $4.66 | $8.85 |
| Interest expense | $0.79 | $3.88 | $3.32 | $3.39 |
| Net income | ||||
| Net income | -$143.47 | $18.89 | $8.98 | $24.87 |
| Income (for common shares) | $18.89 | $8.98 | $24.87 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $674.98 | $666.82 | $541.53 | $429.65 |
| Cost of revenue | $184.67 | $199.29 | $140.25 | $117.33 |
| Gross Profit | $490.31 | $467.53 | $401.28 | $312.32 |
| Operating activities | ||||
| Research & development | $76.26 | $84.8 | $55.55 | $59.42 |
| Selling, general & administrative | $269.44 | $254.52 | $199.34 | $193.52 |
| Total operating expenses | $402.63 | $407.5 | $311.35 | $265.97 |
| Operating income | $87.67 | $60.02 | $89.92 | $46.35 |
| Income from continuing operations | ||||
| EBIT | $82.01 | $53.28 | $88.15 | $45.76 |
| Income tax expense | $19.75 | -$2.61 | $14.42 | -$125.43 |
| Interest expense | $20.31 | $39.98 | $31.75 | $25.67 |
| Net income | ||||
| Net income | $41.95 | $15.91 | $41.98 | $145.52 |
| Income (for common shares) | $41.95 | $15.91 | $41.98 | $145.52 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $18.89 | $8.98 | $24.87 | |
| Operating activities | ||||
| Depreciation | $18.86 | $18.43 | $18.48 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $12.52 | $13.15 | $12.42 | |
| Total cash flows from operations | $53.24 | $49.1 | $47.58 | |
| Investing activities | ||||
| Capital expenditures | -$1.59 | -$2.84 | -$1.8 | |
| Investments | -$13.63 | -$12.69 | $10.17 | |
| Total cash flows from investing | -$82.91 | -$15.21 | -$15.53 | $8.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$23.64 | $1.14 | ||
| Net borrowings | $75.7 | -$2.81 | -$2.81 | |
| Total cash flows from financing | $19.32 | $24.98 | -$2.82 | -$1.78 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $92.67 | $63 | $30.75 | $54.18 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $41.95 | $15.91 | $41.98 | $145.52 |
| Operating activities | ||||
| Depreciation | $75.57 | $91.5 | $28.55 | $19.91 |
| Business acquisitions & disposals | -$32 | -$424.04 | ||
| Stock-based compensation | $47.9 | $48.09 | $42.25 | $39.92 |
| Total cash flows from operations | $154.65 | $145.27 | $125.72 | $77.03 |
| Investing activities | ||||
| Capital expenditures | -$15.16 | -$30.08 | -$45.87 | -$37.8 |
| Investments | $92.7 | -$163.11 | $449.12 | -$239.81 |
| Total cash flows from investing | $77.54 | -$225.19 | -$20.79 | -$277.61 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $4.75 | $27.34 | $26.66 | $102.47 |
| Net borrowings | -$187.68 | -$428.87 | $359.2 | $125.43 |
| Total cash flows from financing | -$183.03 | -$401.53 | $380.69 | $222.3 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $49.16 | -$481.44 | $485.62 | $21.73 |
News
Fundamentals
| Market cap | $1.17B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 46.15M |
| Revenue | $694.96M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$90.73M |
| Revenue Q/Q | 2.83% |
| Revenue Y/Y | 4.40% |
| P/E ratio | -12.94 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.69 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.97 |
|---|---|
| ROA | -5.74% |
| ROE | N/A |
| Debt/Equity | 0.81 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.25 |
| Quick ratio | 1.89 |